Development Strategy of shandong jintai Group Co., Ltd.

Jintai Group takes "high-tech, big medicine, specialization and scale" as the overall development strategy of the group economy. According to the development and changes of the national macro-environment and enterprise micro-environment, in 1999 and 2000, it scientifically formulated the strategic policy of "internal strength and external strength, innovation breakthrough, scientific management and re-development". Now, with a brand-new modern corporate image and excellent business performance, it has diversified and comprehensively explored the international and domestic markets. Among the main products, furazolidone raw materials have won the title of high-quality products of the Ministry and the province for many times, ranking first in the world in production and sales, and exported to more than 30 countries and regions on five continents, and have been praised as "Shandong Yellow" and "Furan King" by domestic and foreign merchants; The new anti-rheumatic drug "Feipuleshu" tablets sell well all over the country and have formed a marketing network in 2/kloc-0 provinces, municipalities and autonomous regions; High-tech bioengineering drugs such as interferon α-2A and interleukin ⅱ have formed large-scale production capacity; At present, more than ten new products are being developed. The building area of 1. 1.000 square meters, which meets GMP standards, has been officially opened; The five production bases of chemical raw materials, preparation drugs, pharmaceutical intermediates and veterinary drugs have an annual output of more than 6,000 tons of nearly 100 varieties of various chemical raw materials and intermediates, and 2.5 billion tablets (granules) of various preparation products.